Cargando…
Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018
BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States of cancers that affect both men and women. Despite strong evidence that screening for CRC reduces incidence and mortality, CRC screening prevalence is below the national target. This report describes...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075255/ https://www.ncbi.nlm.nih.gov/pubmed/32163384 http://dx.doi.org/10.15585/mmwr.mm6910a1 |
_version_ | 1783507005285072896 |
---|---|
author | Joseph, Djenaba A. King, Jessica B. Dowling, Nicole F. Thomas, Cheryll C. Richardson, Lisa C. |
author_facet | Joseph, Djenaba A. King, Jessica B. Dowling, Nicole F. Thomas, Cheryll C. Richardson, Lisa C. |
author_sort | Joseph, Djenaba A. |
collection | PubMed |
description | BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States of cancers that affect both men and women. Despite strong evidence that screening for CRC reduces incidence and mortality, CRC screening prevalence is below the national target. This report describes current CRC screening prevalence by age, various demographic factors, and state. METHODS: Data from the 2018 Behavioral Risk Factor Surveillance System survey were analyzed to estimate the percentages of adults aged 50–75 years who reported CRC screening consistent with the United States Preventive Services Task Force recommendation. RESULTS: In 2018, 68.8% of adults were up to date with CRC screening. The percentage up to date was 79.2% among respondents aged 65–75 years and 63.3% among those aged 50–64 years. CRC screening prevalence was lowest among persons aged 50–54 years (50.0%) and increased with age. Among respondents aged 50–64 years, CRC screening prevalence was lowest among persons without health insurance (32.6%) and highest among those with reported annual household income of ≥$75,000 (70.8%). Among respondents aged 65–75 years, CRC screening prevalence was lowest among those without a regular health care provider (45.6%), and highest among those with reported annual household income ≥$75,000 (87.1%). Among states, CRC screening prevalence was highest in Massachusetts (76.5%) and lowest in Wyoming (57.8%). DISCUSSION: CRC screening prevalence is lower among adults aged 50–64 years, although most reported having a health care provider and health insurance. Concerted efforts are needed to inform persons aged <50 years about the benefit of screening so that screening can start at age 50 years. |
format | Online Article Text |
id | pubmed-7075255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-70752552020-03-23 Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018 Joseph, Djenaba A. King, Jessica B. Dowling, Nicole F. Thomas, Cheryll C. Richardson, Lisa C. MMWR Morb Mortal Wkly Rep Full Report BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States of cancers that affect both men and women. Despite strong evidence that screening for CRC reduces incidence and mortality, CRC screening prevalence is below the national target. This report describes current CRC screening prevalence by age, various demographic factors, and state. METHODS: Data from the 2018 Behavioral Risk Factor Surveillance System survey were analyzed to estimate the percentages of adults aged 50–75 years who reported CRC screening consistent with the United States Preventive Services Task Force recommendation. RESULTS: In 2018, 68.8% of adults were up to date with CRC screening. The percentage up to date was 79.2% among respondents aged 65–75 years and 63.3% among those aged 50–64 years. CRC screening prevalence was lowest among persons aged 50–54 years (50.0%) and increased with age. Among respondents aged 50–64 years, CRC screening prevalence was lowest among persons without health insurance (32.6%) and highest among those with reported annual household income of ≥$75,000 (70.8%). Among respondents aged 65–75 years, CRC screening prevalence was lowest among those without a regular health care provider (45.6%), and highest among those with reported annual household income ≥$75,000 (87.1%). Among states, CRC screening prevalence was highest in Massachusetts (76.5%) and lowest in Wyoming (57.8%). DISCUSSION: CRC screening prevalence is lower among adults aged 50–64 years, although most reported having a health care provider and health insurance. Concerted efforts are needed to inform persons aged <50 years about the benefit of screening so that screening can start at age 50 years. Centers for Disease Control and Prevention 2020-03-13 /pmc/articles/PMC7075255/ /pubmed/32163384 http://dx.doi.org/10.15585/mmwr.mm6910a1 Text en https://creativecommons.org/licenses/by/3.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
spellingShingle | Full Report Joseph, Djenaba A. King, Jessica B. Dowling, Nicole F. Thomas, Cheryll C. Richardson, Lisa C. Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018 |
title | Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018 |
title_full | Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018 |
title_fullStr | Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018 |
title_full_unstemmed | Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018 |
title_short | Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018 |
title_sort | vital signs: colorectal cancer screening test use — united states, 2018 |
topic | Full Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075255/ https://www.ncbi.nlm.nih.gov/pubmed/32163384 http://dx.doi.org/10.15585/mmwr.mm6910a1 |
work_keys_str_mv | AT josephdjenabaa vitalsignscolorectalcancerscreeningtestuseunitedstates2018 AT kingjessicab vitalsignscolorectalcancerscreeningtestuseunitedstates2018 AT dowlingnicolef vitalsignscolorectalcancerscreeningtestuseunitedstates2018 AT thomascheryllc vitalsignscolorectalcancerscreeningtestuseunitedstates2018 AT richardsonlisac vitalsignscolorectalcancerscreeningtestuseunitedstates2018 |